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Abstract 
Alcohol and tobacco have been suggested to be “aggravating factors” for 
neuroprogression in bipolar disorder (BD), however the impact of these substances on the 
underlying neurobiology is limited. Oxidative stress is a key target for research into 
neuroprogression in BD and in accordance with this model, our previous cross-sectional studies 
have found that risky alcohol and tobacco use in BD is associated with increased oxidative stress, 
investigated via in vivo glutathione (GSH) measured by proton magnetic resonance spectroscopy 
(1H-MRS) in the anterior cingulate cortex (ACC). What remains unknown is whether the negative 
impact on GSH levels can be modified as a result of limiting alcohol and tobacco use. 
Thirty BD patients were included in the study. 1H-MRS and tobacco and alcohol 
measures were conducted at baseline and follow-up assessments (15.5 +/- 4.6 months apart). 
Pearson’s correlations were performed between percentage change in ACC-GSH and changes in 
alcohol/tobacco use. Regression analyses were then conducted to further explore the significant 
correlations. An increase in GSH was associated with a decrease in alcohol consumption (r = -
0.381, p < 0.05) and frequency of tobacco use (-0.367, p = 0.05). Change in alcohol 
consumption, tobacco use and age were significant predictors of change in ACC-GSH (F (3, 26) 
= 3.69, p < 0.05). Due to the high comorbidity of alcohol and tobacco use in the sample, the 
individual effects of these substances on GSH levels could not be determined. 
This study offers longitudinal evidence that changing risky drinking patterns and tobacco 
use early in the course of BD is associated with improvements in antioxidant capacity, and 
therefore may be specific targets for early intervention and prevention of neuroprogression in 
BD.  
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Introduction 
Substances of abuse, such as alcohol and tobacco are suggested to be aggravating factors 
for neuroprogression of bipolar disorder (BD) (Berk, 2009, Kapczinski et al., 2008). Accordingly, 
both substances are found to significantly impact illness trajectory, with increased rates of mood 
episode recurrence and severity (Rakofsky and Dunlop, 2013, Salloum et al., 2002, Waxmonsky 
et al., 2005), worsening general function (Cardoso et al., 2008), increased morbidity (Farren et al., 
2012), poorer response to treatment (Berk et al., 2008), lengthier stays in hospital (Dodd et al., 
2010) and increased risk of suicide (Oquendo et al., 2010). Despite the increased understanding 
of the clinical impact of these modifiable environmental exposures (Berk et al., 2011, Berk et al., 
2013) knowledge of the neural interaction between alcohol/tobacco and BD pathophysiology 
remains limited. Thus, research in this area is necessary to enable a better understanding of how 
these factors contribute to poorer outcomes for patients and to help identify neurobiological risk 
factors responsible for the heightened susceptibility of risky drinking and tobacco use in this 
population.  
 Oxidative stress is a key target for research into the neuroprogression of BD (Berk et al., 
2011). Accordingly, ethanol and cigarette smoke have a demonstrated propensity to stimulate the 
formation of reactive oxygen species (ROS) resulting in oxidative stress (Li and Wang, 2004, 
Mendez-Alvarez et al., 1998, Nordmann et al., 1990, Zhang et al., 2007). Neural tissue is 
especially prone to such stress due to its high consumption of oxygen and resultant production 
of ROS, easily oxidisable substrates such as lipids with unsaturated fatty acids and relatively low 
activity of antioxidant defence molecules (Halliwell, 1992; Dringen, 2000; Halliwell, 2006). 
Previously, we have addressed the impact of alcohol and tobacco use on oxidative stress in BD 
by cross-sectionally examining the brain’s primary antioxidant, glutathione (GSH), measured in 
vivo via proton magnetic resonance spectroscopy (1H-MRS) (Chitty et al., 2013, 2014b). We found 
that increased/more frequent alcohol and tobacco use were both negatively associated with GSH 
levels in the anterior cingulate cortex (ACC), and that this effect was specific to BD and not to 
matched controls. Although we were unable to untangle the individual effects of alcohol and 
tobacco use on GSH levels due to high comorbidity of their use in our sample, these findings 
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support the notion that people with BD have an increased propensity for oxidative stress when 
consuming tobacco and risky levels of alcohol, highlighting the importance of the early 
identification and treatment of BD patients who may be susceptible to their use. It is unknown 
whether these initial negative impacts on GSH levels can be modified as a result of limiting 
alcohol and tobacco use, and hence whether these aggravating factors should be specific targets 
of early intervention and prevention of neuroprogression in BD. 
The aim of the present study was to examine longitudinal changes in GSH and its 
relation to self-reported changes in alcohol use patterns and tobacco use among BD patients. We 
examined different components of risky drinking behaviour (e.g. alcohol consumption, problem 
use or the development of dependence) in order to investigate the specific aspects of alcohol use 
that are associated with any corresponding changes in GSH levels. Additionally, we assessed the 
impact of tobacco use on these relationships. We hypothesised that a reduction in risky drinking 
and smoking would be associated with an increase in GSH concentration, reflecting a relaxation 
of oxidative stress. 
 
Patients and Methods 
Participants 
The study was carried out in accordance with the Declaration of Helsinki, and approved 
by the University of Sydney ethics committee. Participants gave written informed consent before 
participation. The sample consisted of the 57 BD participants from our cross-sectional study 
(Chitty et al., 2014b) plus an additional recruitment/inclusion of 20 patients, giving a total of 77 
participants in the study.  
Participants were recruited as part of a wider Youth Mental Health cohort study 
(Hermens et al., 2011, Lee et al., 2013, Scott et al., 2013), with referral from psychiatrists with a 
diagnosed bipolar illness using DSM-IV criteria (APA, 2000) as follows: bipolar I (n = 19), 
bipolar II (n = 30) or bipolar spectrum with family history of BD (n =21) or bipolar NOS (n = 
7), defined as an illness pattern consisting of periods of both elevated and depressed mood 
consistent with a bipolar spectrum disorder (Angst, 2007). Participants were asked at baseline 
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whether they would be interested in being contacted for a follow-up assessment. Thirty-six of 
these patients were followed up after 11 months and all measures were repeated. Researchers 
gave no instruction regarding alcohol or tobacco use before or during the follow-up period. 
Recorded changes at follow-up reflect changes in patients’ self-reported alcohol and tobacco 
habits. Likewise, researchers did not enquire about reasons for any change in substance use at 
follow-up. 
Exclusion criteria for all participants were medical instability, history of neurological 
disease, medical illness known to impact cognitive and brain function, intellectual disability and 
insufficient English for assessment. All participants were asked to abstain from drug or alcohol 
use for 48 hours prior to testing and informed that they may be asked to under-take an alcohol 
breath test and/or a saliva drug screen if the researcher had reason to believe the participant was 
under the influence or intoxicated. Patients’ usual psychotropic medication regimens were not 
interrupted in any way.  
 
Measures 
Clinical and self-report measures 
Participants underwent a clinical interview including the Hamilton Depression Rating 
Scale (HDRS; (Hamilton, 1967), the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 
1962) and the Young Mania Rating Scale (YMRS; Young et al., 1978).  
Participants completed the Alcohol Use Disorders Identification Test (AUDIT) in self-
report format. The AUDIT was developed from a World Health Organisation (WHO) 
collaboration as a screening instrument for hazardous and harmful alcohol consumption 
(Saunders et al., 1993). The tool differs from other screening tests as it emphasizes identification 
of hazardous drinking rather than long-term dependence and focuses primarily on recent 
symptoms and behaviours (Babor et al., 2001), making it more appropriate for youth cohorts 
many of whom will be initiating their drinking habits or will be risky drinkers rather than alcohol 
dependent. The AUDIT is made up of 10 questions, with possible scores ranging from zero 
(abstinence) to 40.  
      7 
 
The AUDIT can be further broken down into sub-scores, which were also calculated at 
each timepoint. The consumption sub-score assesses hazardous alcohol use (e.g. frequency and 
amount of drinking), the dependence sub-score is comprised of symptoms associated with 
dependence (e.g. morning drinking and impaired control over drinking) and the problems sub-
score addresses harmful alcohol use (e.g. alcohol related injuries, blackouts, guilt after drinking 
and concerns of others). A score of 6 – 7 on the consumption sub-score may indicate a risk of 
self-related harm. The dependence score assesses symptoms associated with dependence, a score 
of 4 or more in this sub-score plus a total AUDIT score of 20 or more indicates almost certain 
dependency. Any score on the problems sub-score is indicative of problem drinking. 
Frequency of tobacco use was assessed using baseline and follow-up answers from the 
WHO Alcohol, Smoking and Substance Involvement Screeening Test (WHO-ASSIST) (Edwards 
et al., 2003), in which participants were asked to indicate how often in the previous three months 
they had used tobacco products with ordinal options: never, once or twice, monthly, weekly or 
daily/almost daily.  
Current self-reported symptoms were assessed using the depression anxiety stress scale 
(DASS; Lovibond and Lovibond, 1995)) and the Kessler-10 (K-10), a psychological distress scale 
(Kessler et al., 2002). 
 
1H-MRS data acquisition and processing 
As per previously published protocols (Hermens et al., 2012, Lagopoulos et al., 2013), 
participants were scanned on a 3Tesla GE Discovery MR750 MRI (GE Medical Systems, 
Milwaukee, WI). Firstly, a 3D sagittal whole-brain scout was undertaken for orientation and 
positioning of scans (TR=50ms; TE=4ms; 256matrix; no averaging, z=5mm thickness). Next a 
T1-weighted Magnetization Prepared RApid Gradient-Echo (MPRAGE) sequence producing 
196 sagittal slices (TR=7.2ms; TE=2.8ms; flip angle = 10°; matrix 256x256; 0.9mm isotropic 
voxels) was acquired for the purpose of localization of the ACC. A 2 x 2 x 2 cm single voxel was 
placed midline on the ACC (for example spectra and voxel placement please see (Chitty et al., 
2014a). Spectroscopy data was acquired using PRESS (TE=35ms, TR=2000ms, 128 averages) 
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along with two chemical shift-selective imaging pulses for water suppression. All spectra were 
shimmed to achieve full-width half maximum (FWHM) of <13Hz and visually inspected by 
independent raters. Spectra with the following features were excluded: Cramer–Rao Lower 
Bound greater than 20%, poor spectral morphology (spectra that do not adequately represent 
normal spectra morphology), poor spectral fit (LCModel line fitting that does not adequately 
represent the raw data), large variation in residuals, poor signal-to-noise ratio and presence of 
artefact.  
To obtain reference spectra used to determine GSH quantification, six phantom 
solutions containing varying concentrations of GSH (0 - 7.0 mM) were prepared with 
physiological brain concentrations of creatine, glutamate and glutamine in a phosphate buffer. All 
solutions were kept at 37 °C, and GSH linear dependence was calculated as R2 = 0.994.  
Data were transferred offline for post processing using the LCModel software package 
(Provencher, 1993). All spectra were quantified using a GAMMA-simulated PRESS TE 35 basis 
set of 15 metabolites (including GSH) and incorporated macromolecule and baseline fitting 
routines. Absolute GSH concentration was determined using the ensuing reference spectral 
calibration curve for the ACC.  
Following this, the coordinates of the acquired ACC voxels for each participant were 
obtained using the SAGE (Spectroscopy Analysis GE) software package and the reconstructed 
acquisition voxels for all participants were corrected for grey matter (GM) content. GM 
correction was achieved by segmenting each participant’s structural image into GM, white matter 
and cerebrospinal fluid using the FAST4 algorithm as implemented in FSL (Zhang et al, 2001) 
and volume fractions were calculated. All subsequent statistical analyses were conducted on GM 
corrected absolute GSH concentration.  
 
Statistical analyses 
Statistical analyses were carried out using SPSS for Windows 21.0 (SPSS Inc., Chicago, 
Illinois, USA). Differences in age, symptoms, alcohol, tobacco and medications, and GSH 
concentrations between baseline and follow-up were determined using paired t-tests for string 
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variables or McNemar tests for nominal data (Field, 2013). Alpha was set to 0.05. 
In order to test the primary hypotheses, that decreased drinking and smoking will be 
associated with an increase in GSH, we calculated change scores for AUDIT total and subscores, 
ASSIST tobacco frequency item and GSH concentrations. Raw change scores were used for 
AUDIT and ASSIST and percentage change was used for GSH concentration to take into 
account baseline levels. Values over 100 for “change-GSH” represent an increased concentration 
at follow-up, a positive value for “change-AUDIT” represents an increase in drinking from 
baseline to follow-up and a positive value for “change-tobacco use” indicate a higher frequency 
of tobacco use at follow-up. Pearson’s correlations were performed between change-GSH and 
change-AUDIT and change-tobacco use; co-varying for age at baseline. A simple bootstrapping 
method based on 1000 samples was used to obtain bias-corrected and accelerated (BCa) 95% 
confidence intervals (Wright et al., 2011).  
Hierarchical, robust regression analyses were then conducted to further explore the 
significant correlations. Predictors were entered in two blocks in order to assess the predictive 
value of change-AUDIT separately and then to see the influence of tobacco use on the model. 
Hence, any significant change-AUDIT subscores and age at baseline were entered into Block 1, 
and change-tobacco use at follow-up entered into Block 2. Multicollinearity of predictors was 
assessed by the variance inflation factor (VIF) with values greater than 10 considered as evidence 
of a strong linear relationship between predictors (Myer, 1990).  Cook’s distance was used to 
assess the impact of influential cases with a Cook’s distance of greater than 1 considered a case 
with possible undue influence on the model (Cook & Weisberg, 1982). Standardized residuals 
were inspected to identify outliers, with values +/- 3 standard deviations from the regression line 
considered outliers (Field, 2013).  
 
Results 
Baseline characteristics  
At baseline participants (n = 77) were aged 22.6 +/-3.3 years, duration of illness 7.5 +/- 
3.9 years, years of education 13.0 +/- 2.1 years. Out of the 36 participants who were followed up, 
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six participants were excluded due to invalid spectroscopy data, leaving 30 participants with 
ACC-GSH data at two time points (the “follow-up sample”). Comparisons in baseline 
demographics, ACC-GSH and alcohol and tobacco use between the follow-up sample (n = 30) 
versus those who were only included at baseline (the “baseline-only sample” n = 47) are 
provided in supplementary Table 1. Notably, the baseline-only sample had significantly worse 
HDRS scores at baseline compared with their peers who returned for follow-up (t(70) = 2.15, p 
< 0.05). There were no other significant differences between the groups.  
 
Follow-up sample characteristics 
The follow-up sample (n = 30) included 22 (73.3%) females, aged 22.0 +/- 3.8 years; 
illness duration was 6.89 +/- 3.56 years, years of education 13.3 +/- 2.32. The mean +/- SD 
time between baseline and follow-up was 15.5 +/- 4.6 months (min: 11 months, max: 32 
months) for MRI scans. 
Clinical scores for at baseline and follow-up for the follow-up sample are shown in Table 
1. Self-reported stress and anxiety, as measured by the DASS, as well as clinician ratings (BPRS 
and HDRS scores) were significantly improved at follow-up. There were no significant 
differences in YMRS, K-10 or DASS-depression ratings. 
 
Alcohol, tobacco and medication use  
Table 2 shows the mean scores (and SD) in alcohol, tobacco and medication use over 
time for the follow-up sample. There were no significant changes in alcohol use (as measured by 
AUDIT scores), tobacco use or medications between baseline and follow-up time points.  
 
Longitudinal GSH  
 At the group level, there were no significant differences between ACC-GSH recorded at 
the baseline (1.35+/- 0.42 I.U.) as compared with the follow-up (1.37 +/- 0.33 I.U.) time-point (t 
(29) = 0.17, p > 0.05). Furthermore, the correlation between baseline and follow-up GSH was 
non-significant (R = -0.06, p = 0.757) (see Figure 1). 
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Correlations between change scores 
The correlation matrix (ACC-GSH by four alcohol variables and one tobacco variable) is 
provided in Table 3. Change in ACC-GSH was negatively associated (p < 0.05) with change-
AUDIT consumption score (see Figure 2). Change-tobacco use was negatively associated with 
change-GSH at trend level (p = 0.05). No other correlations between change-GSH and change-
AUDIT/change-tobacco use were found.  
 
Predicting change in ACC-GSH 
 Overall, the regression model was significant (F (2,27) = 3.94, p < 0.05) with change-
AUDIT consumption score and age at baseline explaining 22.6% of the variance in change-GSH. 
Both age (B = -4.14, SE = 1.8, beta = -0.37, p < 0.05, BCa 95% CI – 7.34, -1.3) and change-
AUDIT consumption (B = -8.31, SE = 4.0, beta = -0.37, p < 0.05, BCa 95% CI – 15.8, -1.7) 
were significant predictors of change-GSH, whereby a younger age at baseline and a decrease in 
alcohol consumption was associated with an increased percentage change-GSH. The addition of 
change-tobacco use did not result in a significant change in R2, though the model remained 
significant (F (3, 26) = 3.69, p < 0.05) and explained 29.9% of the variance in change in ACC-
GSH. Age at baseline (B = -3.83, SE = 1.8, beta = -0.35, p < 0.05, BCa 95% CI -7.14, -0.64) and 
change in tobacco use (B = -7.78, SE = 4.3, beta = -0.28, p < 0.05, BCa 95% CI – 13.8, 3.4) were 
significant predictors of increased GSH, with change in AUDIT consumption as a trend-level 
predictor (B = -6.78, SE = 4.1, beta = -0.30, p = 0.097, BCa 95% CI – 14.0, -0.24). VIF values 
were between 1.0 and 1.2. Cook’s distance for all variables was less than 1, and standardized 
residuals were all within three standard deviations. 
 
Discussion 
The aim of the present study was to investigate the relationship between alcohol and 
tobacco use and change in ACC-GSH concentrations over time. Our results confirmed our 
hypotheses; firstly, that a decrease in alcohol consumption, as measured by the AUDIT was 
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associated with increased ACC-GSH and secondly, that a decrease in frequency of tobacco use 
was also associated with increased ACC-GSH over time, albeit with a p-value of 0.05.  
These findings were further supported by a regression model, which identified that a 
decrease in alcohol consumption predicted an increase in GSH. When change in tobacco use was 
entered into the model change in tobacco use and age were significant predictors whereas alcohol 
consumption became only a trend-level predictor (p = 0.097). These results are similar to our 
cross-sectional study (Chitty et al., 2014b), which found that the negative relationship seen 
between AUDIT score and ACC-GSH loses its significance when controlling for smoking status. 
A previous 1H-MRS study revealed that comorbid heavy alcohol use and smoking is associated 
with more pronounced and widespread neurometabolite impairments compared with heavy 
alcohol use alone, suggesting that these two substances may have additive neurobiological 
consequences (Durazzo et al., 2004). Thus, a reasonable interpretation of the present GSH 
findings is that both alcohol and tobacco promote the production of ROS; therefore one would 
expect a greater, combined oxidative effect. To our knowledge no studies have compared clinical 
outcomes in BD in those who use alcohol or tobacco separately vs. those who use these 
substances in conjunction. This lack of evidence is likely due to the same limitation faced here; 
that is, the high prevalence of comorbid alcohol and tobacco use in BD, hence the individual 
effects of each substance are difficult to tease apart without large sample sizes. Consequently it is 
unclear whether the compounded neurobiological effects of the alcohol-tobacco comorbidity is 
associated with a greater impact on neuroprogression of BD, nonetheless it would be logical to 
speculate that they do 
Younger age at baseline was a predictor of increased percentage change-GSH at follow-
up. This may suggest that the effect of alcohol and tobacco on GSH levels varies depending on 
age, with younger patients more resilient to decreases in anti-oxidant capacity. A rodent study has 
also implicated the role of age on GSH synthesis after acute ethanol exposure (Sommavilla et al., 
2012) and many other rodent studies have identified developmental changes in antioxidant 
capacity (Hussain et al., 1995; Siqueira et al., 2005; Beiswanger et al., 1995). This collective 
evidence suggests that age most probably has a role to play in the effects that toxic substances 
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have on oxidative stress systems, highlighting the importance of early intervention of alcohol and 
tobacco risk management in BD. 
While there was no between-subjects difference in ACC-GSH levels from baseline to 
follow-up, there was also no within-subject correlation between baseline and follow-up GSH 
concentrations and inspection of Figure 1 suggests that there were substantial between-subject 
differences in the fluctuation of GSH across time points. This is likely due to differences in GSH 
consumption and de novo synthesis based on oxidative stress states (Dringen, 2000; Dringen and 
Hirrlinger, 2003). Whereby higher levels of alcohol and/or tobacco consumption promote the 
production of ROS (Nordmann et al., 1990; Zhong et al., 2012; Zhang et al., 2007), leading to 
higher GSH consumption (Janaky et al., 1993). 
There were no significant correlations between ACC-GSH and change in dependent and 
problematic drinking as measured by the AUDIT. These findings indicate that specifically 
decreasing the amount and frequency of alcohol consumption is associated with improved 
antioxidant capacity in BD. This may suggest that problematic drinking and/or alcohol 
dependence is not associated with GSH or that changes in such drinking behaviours are not 
linked to potential changes in GSH synthesis or consumption. It is noteworthy that during 
adolescence and young adulthood, alcohol dependence is not common, whereas alcohol abuse 
patterns (i.e. binge/risky drinking) do emerge and are prevalent, hence alcohol consumption may 
be the most important indicator of future dependence patterns. 
Limitations 
There are several limitations to consider when interpreting these study results. Firstly, 
due to the sample size of the study only three predictors were possible to add to the regression 
model, limiting our assessment of other factors that may have predicted change in GSH-ACC. 
For example, participants showed significantly improved clinical outcomes at follow-up. While 
this is most likely a consequence of continued clinical care it may be related to improved 
neurobiological measures. Given that overall participants were significantly improved in clinical 
measures without significant overall change in ACC-GSH, it may not be that the two are related. 
However it does present a confounding factor in our analyses and one that should be 
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investigated further with a larger sample size for regression. Also our study has used multiple 
correlations to explore the relationship between GSH and change in alcohol and tobacco use and 
as a result the reader must be advised there is a risk of Type I error. Furthermore, quantifying 
GSH concentration via 1H-MRS is a new technique, which limits our ability to make inferences 
about what changes in GSH are showing. To our knowledge there is no data available that shows 
the test-retest reliability and normal fluctuation of GSH levels measured via 1H-MRS. Likewise, 
we have not collected longitudinal GSH control data, limiting our ability to speculate as to how 
much of this variation is random individual variation in GSH. In light of these limitations we 
advise the reader that these results are preliminary. 
Alcohol status at baseline was significantly different between those in the baseline-only 
sample vs. those in the follow-up sample, with more risky drinkers in the baseline sample (as well 
as a higher mean HDRS). We speculate that those in the baseline-only sample with higher levels 
of drinking may have presented with decreased GSH at follow-up, given they maintained their 
risky drinking patterns. Further research into the effects of maintaining risky drinking over many 
years is necessary.  
Participants were on an array of medications. Although there was no significant 
difference in patients that remained on or off medications, there is the possibility that some 
medications may have influenced ACC-GSH. For example, lithium has been shown to have 
neuroprotective effects (de Sousa et al., 2014). A larger sample size would allow us to look 
further into the effect of medications on this relationship. 
Conclusions 
It has been proposed that BD is a neuroprogresssive disorder partly associated with 
inadequately compensated metabolic stress, and that this neuroprogression has the potential for 
modifiable pathophysiology over the course of the illness (Berk et al., 2011, Post, 2007). 
Oxidative stress is implicated in this progression and acceleration of disease processes in BD 
(Berk et al., 2011), hence our cumulative results suggest that risky alcohol use may contribute to 
the neuroprogressive process and, indeed, may explain the heightened negative consequences 
documented in those with this cormorbidity. Importantly, the present study offers longitudinal 
      15 
 
evidence that shows changing risky drinking patterns and tobacco use early in the course of 
illness is associated with improvements in ACC-GSH, and therefore may be early modifiable risk 
factors for heightened neuroprogression. In addition, augmentation of GSH has been identified 
as a targeted pathway for neuroprotection in BD (Berk et al., 2011). Thus, our results stress the 
importance of monitoring alcohol and tobacco use from first presentation of BD symptomology 
and importantly, further highlight alcohol and tobacco reduction as a first-line treatment avenue. 
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